NDAORALTABLET
Approved
Jul 2011
Lifecycle
Peak
Competitive Pressure
0/100
Clinical Trials
20
Data completeness
5/8 — Partial
XARELTO (rivaroxaban) by Johnson & Johnson is factor xa inhibitors [moa]. Approved for factor xa inhibitor [epc]. First approved in 2011.
Drug data last refreshed Yesterday · AI intelligence enriched 1w ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
XARELTO (rivaroxaban) is an oral Factor Xa inhibitor approved in 2011 for prevention and treatment of venous thromboembolism, including deep vein thrombosis and pulmonary embolism, as well as stroke prevention in atrial fibrillation. It works by selectively inhibiting Factor Xa, a key enzyme in the coagulation cascade, thereby reducing thrombin generation and thrombus formation without requiring antithrombin III as a cofactor.
Peak8.3 years to LOE
XARELTO maintains peak revenue at $6.3B but faces significant competitive pressure from ELIQUIS ($18.3B), suggesting stable but defensive positioning that requires strong field execution and market access strategies.
Mechanism of Action
Factor Xa Inhibitors
Pharmacologic Class:
Factor Xa Inhibitor
Indications
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Clinical Trials (20)
A Study to Observe the Pattern of Use and Safety of Rivaroxaban in Children Under 2 Years Old With Venous Thromboembolism (VTE)
Started Sep 2026
850 enrolled
Venous ThromboembolismChildren Under 2 Years
Aspirin or Rivaroxaban Thromboprophylaxis for Patients With Multiple Myeloma
Started Sep 2025
530 enrolled
Multiple MyelomaVenous Thromboembolism
An Observational Study to Learn More About the Safety of Rivaroxaban in Participants With Peripheral Arterial Disease Who Had Surgery to Improve Blood Flow to Their Legs
Started Aug 2025
1,500 enrolled
Peripheral Arterial Disease (PAD)
Assessment of Gastrointestinal Blood Loss After Receiving Aspirin or Aspirin Plus Rivaroxaban, or Aspirin Plus REGN9933, or Aspirin Plus REGN7508 in Healthy Adult Participants
Started Sep 2024
224 enrolled
Healthy Volunteers
An Observational Study to Learn More About How Safe Rivaroxaban is And How Well it Works in Children With Congenital Heart Disease Who Had a Heart Surgery Called the Fontan Procedure
Started Jun 2024
61 enrolled
Prevention of Venous ThromboembolismCongenital Heart DiseaseFontan Procedure+1 more
Worked on XARELTO at Johnson & Johnson? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.